Introduction
Adverse reactions affecting the eyes have been described with several 1-adrenoreceptor blocking agents, principally practolol. Both propranolol and oxprenolol have been incriminated in causing ocular symptoms but there are no reported instances of ocular damage due to timolol. The patient reported here developed dryness of the eyes, which improved subjectively on withdrawal of timolol.
Case report
A 40-year-old Caucasian fireman was discovered to have raised blood pressure on medical examination to assess fitness for use of breathing apparatus. He had no symptoms, nor had he suffered serious ill health in the past. Examination 
Comment
The adverse effects of practolol on the eyes were first described 4 years after the introduction of the drug, as were the cutaneous manifestations of hypersensitivity (Wright, 1974; Felix, Ive and Dahl, 1974) . Holt and Waddington (1975) reported an oculocutaneous reaction to oxprenolol, and propranolol has been reported as causing an ocular reaction which resolved on changing the n-blocker (Cubey and Taylor, 1975 The patient reported here developed irritating dryness of the eyes and nose shortly after starting treatment with timolol. Conjunctival epithelial and corneal changes developed and there was a marked reduction in tear volume. Subjectively, he was improved on withdrawal of the drug. Objectively, tear production was not improved but the epithelial changes had nearly resolved and the corneal abnormalities were completely healed. Rahi et al. (1976) described a fibrosing polyserositis affecting the eyes, with acanthosis, and thickening of, and loss of goblet cells from, the epithelium, and chronic inflammatory changes during treatment with r-blockers. The cornea showed epitheliolysis and stromal ulceration, inadequate tear production leading to epidermalization of the conjunctival epithelium -similar changes to those found in the present patient.
These changes have been found in association with an autoantibody with affinity for intercellular zones of squamous epithelium. A significant increase in antinuclear antibody titre has been described in patients taking practolol, as well as thyroid cytoplasmic antibody. These serological changes did not, however, correlate with the development of the oculo-cutaneous syndrome (Jachuck et al., 1977) . In the present patient thyroglobulin antibody tests were negative as were flurescent antibody tests, although RA latex test was positive.
Although the ocular side effects described here are not as well developed as those seen with practolol, the resemblance and the onset and partial clearing in 0032-5473/79/1200-0884 $02.00 ©J 1979 The Fellowship of Postgraduate Medicine relation to treatment with timolol suggest that the drug or a metabolite was responsible. In this patient there is no evidence that the adverse effects were of immunological cause. Such ocular damage may possibly occur with any of the 3-adrenoreceptor blocking drugs. The absence of reports may be due to the failure of the patient to report and the doctor to enquire about symptoms, and the failure of doctors to notify the COSM.
